Trial reportDrug and alcohol dependence2020
Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.
Trial report in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- The 5-HTPharmacology research & perspectives · 2021Trial
- Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.Drug and alcohol dependence · 2021Trial
- Improving translational insight using sequential sampling models in drug choice.Psychopharmacology · 2026Review
- Nonpharmacological and pharmacological influences on opioid effects: A review of clinical research findings.The Journal of pharmacology and experimental therapeutics · 2025Review
- Lorcaserin modulation of semantic drug cue-elicited effective brain connectivity in persons with cocaine and opioid use disorders.Psychiatry research. Neuroimaging · 2025Article
- Applications of artificial intelligence in drug discovery for neurological diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options.Pharmacology, biochemistry, and behavior · 2024Review
- Interactions between lorcaserin and opioids: Ventilation and food-versus-drug choice.Pharmacology, biochemistry, and behavior · 2024Article
- Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments.Pharmacological reviews · 2023Review
- Neural circuits controlling choice behavior in opioid addiction.Neuropharmacology · 2023Review
- Logical fallacies and misinterpretations that hinder progress in translational addiction neuroscience.Journal of the experimental analysis of behavior · 2022Article
- Contextual extinction of drug-associated discriminative stimuli fails to attenuate drug-vs-food choice in rhesus monkeys.Journal of the experimental analysis of behavior · 2022Article
- Lack of effect of the nociceptin opioid peptide agonist Ro 64-6198 on pain-depressed behavior and heroin choice in rats.Drug and alcohol dependence · 2022Article
- Confronting the challenge of failed translation in medications development for substance use disorders.Pharmacology, biochemistry, and behavior · 2021Article
- Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys.Drug and alcohol dependence · 2021Article
- Animal Models of Drug Relapse and Craving after Voluntary Abstinence: A Review.Pharmacological reviews · 2021Review
- 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.Addiction biology · 2021Article
- Improving Translational Research Outcomes for Opioid Use Disorder Treatments.Current addiction reports · 2021Article
- Improving translation of animal models of addiction and relapse by reverse translation.Nature reviews. Neuroscience · 2020Review
- Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLorcaserin, a high-affinity 5-HT
methodsIn this 7-week inpatient trial, 12 non-treatment-seeking volunteers (11 males) with moderate-to-severe opioid use disorder were detoxified from opioids. In a randomized cross-over fashion, participants were first stabilized on lorcaserin (10 mg BID) or placebo (0 mg BID). Participants underwent a two-week testing period during which the reinforcing and subjective effects of intranasal oxycodone were examined in verbal choice, cue-exposure, and progressive-ratio choice sessions. The two testing weeks were identical with the exception that during the first week, active oxycodone (10 mg) was available during verbal choice (self-administration) sessions, and during the second week placebo oxycodone was available. Subsequently, participants were stabilized on the other medication condition (placebo or lorcaserin) and underwent the same testing procedures again.
resultsLorcaserin did not alter oxycodone self-administration. However, lorcaserin had a trend to increase "wanting heroin" when oxycodone was available, and to accentuate oxycodone-induced miosis.
conclusionUnder the current experimental conditions, lorcaserin at a dose of 10 mg BID did not reliably decrease the abuse liability of oxycodone, even though the study was sufficiently powered (≥80 %) to detect clinically meaningful differences in the main outcome variables between the placebo and active lorcaserin condition. Future research could explore a wider dose range of lorcaserin and oxycodone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.